{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:07:16Z","timestamp":1779199636584,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xjidi.2026.100457","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:31:52Z","timestamp":1770683512000},"page":"100457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-1447","authenticated-orcid":false,"given":"Saeko","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0844-9369","authenticated-orcid":false,"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-1227","authenticated-orcid":false,"given":"Kei","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4265-8827","authenticated-orcid":false,"given":"Noriaki","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3090-2851","authenticated-orcid":false,"given":"Kotaro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8643-0014","authenticated-orcid":false,"given":"Takuya","family":"Takafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4370-7594","authenticated-orcid":false,"given":"Yoshihito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0554","authenticated-orcid":false,"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100457_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74798-z","article-title":"Epigenetic alterations in skin homing CD4+CLA+ T cells of atopic dermatitis patients","volume":"10","author":"Acevedo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2026.100457_bib2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nchembio.1230","article-title":"Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives","volume":"9","author":"Anguiano","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.xjidi.2026.100457_bib3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/ijms24031899","article-title":"SOMAscan proteomics identifies novel plasma proteins in amyotrophic lateral sclerosis patients","volume":"24","author":"Berrone","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xjidi.2026.100457_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2026.100457_bib5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/cea.14442","article-title":"Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation","volume":"54","author":"Boesjes","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.xjidi.2026.100457_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamadermatol.2023.2609","article-title":"Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab","volume":"159","author":"Deng","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2026.100457_bib7","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.3390\/ijms24065968","article-title":"mTORC1 deficiency prevents the development of MC903-induced atopic dermatitis through the downregulation of Type 2 inflammation","volume":"24","author":"Gupta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xjidi.2026.100457_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2026.100457_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2026.100457_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202100097","article-title":"Clinical applications of plasma proteomics and peptidomics: towards precision medicine","volume":"16","author":"He","year":"2022","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.xjidi.2026.100457_bib11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","article-title":"Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers","volume":"11","author":"He","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100457_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.02.001","article-title":"New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity","volume":"70","author":"Kabashima","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.xjidi.2026.100457_bib13","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.xjidi.2026.100457_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100457_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100457_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cells8060591","article-title":"Rho GTPases in the physiology and pathophysiology of peripheral sensory neurons","volume":"8","author":"Kalpachidou","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.xjidi.2026.100457_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jid.2022.08.048","article-title":"Quantitative proteomics identifies reduced NRF2 activity and mitochondrial dysfunction in atopic dermatitis","volume":"143","author":"Koch","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100457_bib18","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1021\/acs.jproteome.4c00411","article-title":"Crossing the halfway point: aptamer-based, highly multiplexed assay for the assessment of the proteome","volume":"23","author":"Kraemer","year":"2024","journal-title":"J Proteome Res"},{"key":"10.1016\/j.xjidi.2026.100457_bib19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in Ingenuity Pathway Analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xjidi.2026.100457_bib20","article-title":"Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): a novel population in the tumour microenvironment and immunotherapy target","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.xjidi.2026.100457_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942838","article-title":"Post-translational modifications in atopic dermatitis: current research and clinical relevance","volume":"10","author":"Ma","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.xjidi.2026.100457_bib22","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/all.16183","article-title":"Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions","volume":"79","author":"Nakajima","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2026.100457_bib23","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.xjidi.2026.100457_bib24","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.3390\/jcm10245947","article-title":"The role of extracellular matrix in skin wound healing","volume":"10","author":"Potekaev","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.xjidi.2026.100457_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.xjidi.2026.100457_bib26","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3390\/cells12121671","article-title":"The PI3K-Akt-mTOR and associated signaling pathways as molecular drivers of immune-mediated inflammatory skin diseases: update on therapeutic strategy using natural and synthetic compounds","volume":"12","author":"Roy","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.xjidi.2026.100457_bib27","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1038\/s41467-023-41857-8","article-title":"Multifaceted analysis of cross-tissue transcriptomes reveals phenotype-endotype associations in atopic dermatitis","volume":"14","author":"Sekita","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2026.100457_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","article-title":"Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents","volume":"12","author":"Sidbury","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.xjidi.2026.100457_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.722170","article-title":"Periostin in allergy and inflammation","volume":"12","author":"Sonnenberg-Riethmacher","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100457_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ada.2019.88394","article-title":"Cytokines and apoptosis in atopic dermatitis","volume":"38","author":"Szyma\u0144ski","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.xjidi.2026.100457_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i01","article-title":"Elastic net regularization paths for all generalized linear models","volume":"106","author":"Tay","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.xjidi.2026.100457_bib32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2026.100457_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"10.1016\/j.xjidi.2026.100457_bib34","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/cea.12979","article-title":"Identification of unique proteomic signatures in allergic and non-allergic skin disease","volume":"47","author":"Wang","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.xjidi.2026.100457_bib35","article-title":"Chaperone-mediated autophagy: molecular mechanisms, biological functions, and diseases","volume":"4","author":"Yao","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.xjidi.2026.100457_bib36","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.3390\/ijms23073467","article-title":"Role of ERK pathway in the pathogenesis of atopic dermatitis and its potential as a therapeutic target","volume":"23","author":"Zeze","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xjidi.2026.100457_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.890121","article-title":"Association between Neddylation and immune response","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Cell Dev Biol"}],"updated-by":[{"DOI":"10.1016\/j.xjidi.2026.100469","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000}}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:12:06Z","timestamp":1779196326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2667026726000093"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100457","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100457"}}